Aggregation of Monoclonal Antibody Products: Formation and Removal - Aggregate formation is influenced by multiple aspects of the bioproduction process but can be mitigated by good process design and

ADVERTISEMENT

Aggregation of Monoclonal Antibody Products: Formation and Removal
Aggregate formation is influenced by multiple aspects of the bioproduction process but can be mitigated by good process design and control.


BioPharm International
Volume 26, Issue 3, pp. 40-45


Anurag S. Rathore
Monoclonal antibody (mAb) products have emerged as an extremely important and valuable class of therapeutic products for the treatment of cancer and other diseases such as rheumatoid arthritis, auto-inflammatory disease, allergic asthma, and multiple sclerosis (1, 2). The proliferation of this product class has led to significant advancements in the production processes that are used to manufacture them. However, product aggregation remains a crucial issue and results not only in product loss but also affects product safety (3).


Figure 1: Illustration of the different pathways that result in mAb aggregation.
Aggregates are typically large, tangled clusters of denatured antibody molecules that are irreversibly formed either during product expression in the cell culture, product purification in downstream processing, or storage as drug substance or drug product (see Figure 1). The process of aggregation is influenced by the biochemical and biophysical properties of the mAb itself, as well as the physicochemical environment to which the mAb is exposed during processing and storage (4).

Aggregation can cause formation of subvisible particles and may expose normally unexposed epitopes, leading to increased immunogenicity. The subvisible particles have become of increasing concern to the regulatory agencies because of the difficulty in detecting them and their potential for causing unintended immunogenicity. Subvisible particles, defined as particles larger than 0.1 Ám but too small to be visible to the unaided eye (i.e., < 100 Ám), may form either during product manufacture or storage. Of particular concern are particles less than 10 Ám in size, which are not well detected by current analytical methods used to monitor degradation of mAb products. Purification processes for mAb products should be capable of achieving low aggregate levels (i.e., 0.5–2%). The relatively large, irreversible aggregates are different from the often reversible dimers and trimers that are often less of a concern. Individual antibodies vary widely in their propensity to form aggregates (5). Extremes of pH, ionic strength, temperature, concentration, shear forces, and other processing conditions can lead to increased aggregation. As a result, aggregation has to be monitored throughout process development and manufacturing of a mAb product.

During manufacturing of protein therapeutics, the protein is exposed to various stresses. The cell-culture phase of a typical mAb production process improves secretion of the protein from the cell into the medium, which contains the cells, buffer constituents, nutrients for the cells, host-cell proteins (including proteases), dissolved oxygen, and other species. This cellular suspension is held at near neutral pH at temperatures above 30 ░C for several days. Once a sufficient amount of protein has been expressed, the cell-culture fluid is harvested and purified with Protein A chromatography. The resulting pool is often held at acidic pH for viral inactivation. Polishing steps that typically follow include cation-exchange chromatography (CEX), which is performed under conditions of high conductivity, and anion-exchange chromatography (AEX), which is performed at high pH. Finally, the protein is formulated using ultrafiltration/diafiltration and filled in its final form. Throughout the production process, the protein solution is pumped, stirred, and filtered and is exposed to a variety of materials including stainless steel, glass, and plastic. All of these factors can potentially result in aggregate formation (6).


Elements of Biopharmaceutical Production
This article, 29th in the "Elements of Biopharmaceutical Production" series, presents a discussion of the factors that result in formation as well as control of mAb aggregates during processing.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International,
Click here